<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033825</url>
  </required_header>
  <id_info>
    <org_study_id>060-610</org_study_id>
    <nct_id>NCT01033825</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis</brief_title>
  <official_title>A 6-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of the Potential Inhibitory Effects on the Hypothalamic-Pituitary-Adrenal Axis of Ciclesonide HFA Nasal Aerosol and Ciclesonide Aqueous Nasal Spray in Subjects 12 Years and Older With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous
      (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety
      and efficacy study of the effects of ciclesonide HFA nasal aerosol and ciclesonide AQ nasal
      spray on the HPA axis, when administered once daily to male and female subjects 12 years or
      older diagnosed with Perennial Allergic Rhinitis (PAR). The study consists of a screening
      period, a single blind run in period, a 6 week double blind treatment period including an
      active control segment, and a follow up period.

      Placebo was used as the control during the double-blind treatment period for both delivery
      methods (HFA nasal aerosol and aqueous nasal spray)and for the study outcome analyses. There
      was also a positive control administered to a subset of these placebo subjects during the
      last 4 days of Week 6 (dexamethasone placebo or dexamethasone 6 mg). The active control was
      utilized to validate the assay sensitivity (ie, distinguish an effective from an ineffective
      drug) of this study, as dexamethasone is a known HPA axis suppressant, therefore this subset
      of placebo subjects was not included in the study outcome analyses.

      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC(0-24h) will be computed using the linear trapezoidal rule based on the actual time of serum cortisol drawing. AUC(0-24) is then approximated by the sum of the areas of trapezoids. The trapezoid for each time interval is based on the actual times of non-missing cortisol values, and is defined by the actual time interval as the base, the line connecting the two cortisol values, and the two vertical sides at the two time points. Raw data is presented for baseline values (i.e. mean/SD), while inferential statistics are presented for week 6 values (i.e. LS mean/SE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) From Baseline to Week 6 of the Double Blind Treatment Period</measure>
    <time_frame>week 6</time_frame>
    <description>Change is calculated as week 6 minus baseline. AUC(0-24h) will be computed using the linear trapezoidal rule based on the actual time of serum cortisol drawing. AUC(0-24) is then approximated by the sum of the areas of trapezoids. The trapezoid for each time interval is based on the actual times of non-missing cortisol values, and is defined by the actual time interval as the base, the line connecting the two cortisol values, and the two vertical sides at the two time points. Raw data is presented for baseline values (i.e. mean/SD), while inferential statistics are presented for week 6 values (i.e. LS mean/SE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Adverse Events (AEs)</measure>
    <time_frame>Weeks 0-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Experiencing Adverse Events (AEs)</measure>
    <time_frame>Weeks 0-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Serious Adverse Events (SAEs).</measure>
    <time_frame>Weeks 0-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Experiencing Serious Adverse Events (SAEs).</measure>
    <time_frame>Weeks 0-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Discontinue Due to AEs</measure>
    <time_frame>Weeks 0-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Discontinue Due to AEs</measure>
    <time_frame>Weeks 0-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Local Nasal AEs</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>Local Nasal adverse events are defined as adverse events occurring in the middle ear, nose, throat, and upper respiratory tract down to the larynx, anatomic regions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Experiencing Local Nasal AEs</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>Local Nasal adverse events are defined as adverse events occurring in the middle ear, nose, throat, and upper respiratory tract down to the larynx, anatomic regions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-12h) at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-12h) From Baseline After 6 Weeks of Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cortisol Area Under the Concentration-time Curve (AUC)(12-24h) at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(12-24h) From Baseline After 6 Weeks of Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported AM Reflective TNSS</measure>
    <time_frame>Baseline</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported PM Reflective TNSS</measure>
    <time_frame>Baseline</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported AM Instantaneous TNSS</measure>
    <time_frame>Baseline</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported AM and PM Reflective TNSS</measure>
    <time_frame>Baseline</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over Each Week, and Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported PM Instantaneous TNSS</measure>
    <time_frame>Baseline</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported PM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported AM and PM Instantaneous TNSS</measure>
    <time_frame>Baseline</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported Individual AM Reflective NSS</measure>
    <time_frame>Baseline</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported Individual PM Reflective NSS</measure>
    <time_frame>Baseline</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual PM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported Individual AM and PM Reflective NSS</measure>
    <time_frame>Baseline</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported Individual AM Instantaneous NSS</measure>
    <time_frame>Baseline</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported Individual PM Instantaneous NSS</measure>
    <time_frame>Baseline</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual PM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Daily Subject-reported Individual AM and PM Instantaneous NSS</measure>
    <time_frame>Baseline</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximal Effect Over 6 Weeks of Double-blind Treatment.</measure>
    <time_frame>Weeks 0-6</time_frame>
    <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between each active treatment group and corresponding placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day. The evaluation is made separately for each dose level of Ciclesonide HFA compared to placebo. Difference is calculated as placebo - ciclesonide. Analysis of HFA data and AQ data were conducted separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio (Percentage) of Correct Advances of the Dose Indicator Out of Expected Advances.</measure>
    <time_frame>Weeks 1-2, 2-4</time_frame>
    <description>Ratio of correct advance is defined as the (number of doses actuated/number of dose reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Devices With Actuation Consistency</measure>
    <time_frame>Weeks 1-4</time_frame>
    <description>Actuation consistency is defined as a dose indicator count within ±20% of the subject self report of study medication administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Devices With Actuation Consistency</measure>
    <time_frame>Weeks 1-4</time_frame>
    <description>Actuation consistency is defined as a dose indicator count within ±20% of the subject self report of study medication administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Devices With Major Discrepancies</measure>
    <time_frame>Week 6</time_frame>
    <description>A major discrepancy is defined as a discrepancy of &gt;20 actuations between the dose indicator and subject self report of study medication administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Devices With Major Discrepancies</measure>
    <time_frame>Week 6</time_frame>
    <description>A major discrepancy is defined as a discrepancy of &gt;20 actuations between the dose indicator and subject self report of study medication administration.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">310</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Ciclesonide HFA Nasal Aerosol 320 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide HFA Nasal Aerosol 160 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFA Nasal Aerosol placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HFA Nasal Aerosol Placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciclesonide Aqueous Nasal Spray 200 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AQ Nasal Spray Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AQ Nasal Spray Placebo once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo HFA plus Dexamethasone 6 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo HFA plus Dexamethasone 6 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo AQ plus Dexamethasone 6 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo AQ plus Dexamethasone 6 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide HFA Nasal Aerosol 320 mcg</intervention_name>
    <description>Ciclesonide HFA Nasal Aerosol 320 μg once daily</description>
    <arm_group_label>Ciclesonide HFA Nasal Aerosol 320 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide HFA Nasal Aerosol 160 mcg</intervention_name>
    <description>Ciclesonide HFA Nasal Aerosol 160 μg once daily</description>
    <arm_group_label>Ciclesonide HFA Nasal Aerosol 160 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HFA Nasal Aerosol placebo</intervention_name>
    <description>HFA Nasal Aerosol placebo once daily</description>
    <arm_group_label>HFA Nasal Aerosol placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide Aqueous Nasal Spray 200 mcg</intervention_name>
    <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
    <arm_group_label>Ciclesonide Aqueous Nasal Spray 200 mcg</arm_group_label>
    <other_name>Omnaris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQ Nasal Spray Placebo</intervention_name>
    <description>AQ Nasal Spray Placebo once daily</description>
    <arm_group_label>AQ Nasal Spray Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus Dexamethasone HFA</intervention_name>
    <description>Dexamethasone capsules 6 mg once daily</description>
    <arm_group_label>Placebo HFA plus Dexamethasone 6 mcg</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo AQ plus Dexamethasone 6 mg</intervention_name>
    <description>Placebo AQ plus Dexamethasone 6 mcg capsules once daily</description>
    <arm_group_label>Placebo AQ plus Dexamethasone 6 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give written informed consent and assent, including privacy authorization as well as
             adherence to concomitant medication withholding periods, prior to participation.

          -  Subject must be in general good health (defined as the absence of any clinically
             relevant abnormalities as determined by the Investigator) based on screening physical
             examination, medical history, and clinical laboratory values (Hematology, Chemistries
             and Urinalysis).

          -  If any of the screening Hematology, Chemistries, or Urinalysis are not within the
             clinical laboratory's reference range, then the subject can be included only if the
             Investigator judges the deviations to be not clinically significant.

          -  A history of PAR to a relevant perennial allergen (house dust mites, cockroach, molds,
             animal dander) for a minimum of two years immediately preceding the study Screening
             visit. The PAR must have been of sufficient severity to have required treatment
             (either continuous or intermittent) in the past and require treatment throughout the
             entire study period.

          -  A demonstrated sensitivity to at least one allergen known to induce PAR (house dust
             mite, animal dander, cockroach, and molds) based on a documented result with a
             standard skin-prick test either within 90 days prior to screening or performed at the
             Screening visit. A positive test is defined as a wheal diameter at least 3 mm larger
             than the negative control wheal for the skin prick test. The subject's positive
             allergen test must be consistent with the medical history of PAR and must be present
             in the subject's environment throughout the study.

          -  Subject, if female, must have a negative serum pregnancy test at screening. Females of
             childbearing potential must be instructed to and agree to avoid pregnancy during the
             study and must use an acceptable method of birth control.

               1. An oral contraceptive, an intrauterine device (IUD), implantable contraceptive,
                  transdermal or injectable contraceptive for at least 1 month prior to entering
                  the study with continued use throughout the study and for thirty days following
                  study participation.

               2. Barrier method of contraception, eg, condom and/or diaphragm with spermicide
                  while participating in the study.

               3. Abstinence.

        Exclusion Criteria:

          -  Female subject who is pregnant or lactating.

          -  History of physical findings of nasal pathology, including nasal polyps or other
             clinically significant respiratory tract malformations; recent nasal biopsy; nasal
             trauma; or nasal ulcers or perforations. Surgery and atrophic rhinitis or rhinitis
             medicamentosa are not permitted within the last 120 days prior to the Screening visit.

          -  Subject is, in the investigator's judgement, having a seasonal exacerbation at the
             time of screening.

          -  Participation in any investigational drug trial within the 30 days preceding the
             Screening visit or planned participation in another investigational drug trial at any
             time during this trial.

          -  A known hypersensitivity to any corticosteroid or any of the excipients in the
             formulation of ciclesonide.

          -  History of a respiratory infection or disorder [including, but not limited to
             bronchitis, pneumonia, influenza, severe acute respiratory syndrome (SARS)] within the
             14 days preceding the Screening visit.

          -  History of alcohol or drug abuse within 2 years preceding the Screening visit.

          -  History of a positive test for HIV, hepatitis B or hepatitis C.

          -  Active asthma requiring treatment with inhaled or systemic corticosteroids and/or
             routine use of beta agonists and any controller drugs (eg, theophylline, leukotriene
             antagonists, etc.); intermittent use (less than or equal to 3 uses per week) of
             inhaled short acting beta-agonists is acceptable. Use of short acting beta-agonists
             for exercise-induced bronchospasm will be allowed.

          -  Expected use of any disallowed concomitant medications during the treatment period.

          -  Initiation of immunotherapy during the study period or dose escalation during the
             study period. However, initiation of immunotherapy 90 days or more prior to the
             Screening Visit and use of a stable (maintenance) dose (30 days or more) may be
             considered for inclusion.

          -  Previous randomization in an intranasal ciclesonide HFA nasal aerosol study.

          -  Non-vaccinated exposure to or active infection with, chickenpox or measles within the
             21 days preceding the Screening Visit.

          -  Initiation of pimecrolimus cream 1% or greater or tacrolimus ointment 0.03% or greater
             during the study period or planned dose escalation during the study period. However,
             initiation of these creams/ointments 30 days or more prior to screening and use of a
             stable (maintenance) dose during the study period may be considered for inclusion.

          -  Study participation by clinical investigator site employees and/or their immediate
             relatives who reside in the same household.

          -  Study participation by more than one subject from the same household.

          -  Have any of the following conditions that are judged by the investigator to be
             clinically significant and/or affect the subject's ability to participate in the
             clinical trial: impaired hepatic function including alcohol related liver disease or
             cirrhosis; history of ocular disturbances, eg, glaucoma or posterior subcapsular
             cataracts; any systemic infection hematological, hepatic, renal, endocrine (except for
             controlled diabetes mellitus or postmenopausal symptoms or hypothyroidism;
             gastrointestinal disease; malignancy (excluding basal cell carcinoma); current
             neuropsychological condition with or without drug therapy

          -  Any condition that, in the judgment of the investigator, would preclude the subject
             from completing the protocol with capture of the assessments as written.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Medical Research Associates</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneappolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Center for Clinical Research</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <results_first_submitted>February 15, 2012</results_first_submitted>
  <results_first_submitted_qc>July 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2012</results_first_posted>
  <disposition_first_submitted>September 17, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 17, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 21, 2010</disposition_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ciclesonide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
          <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
        </group>
        <group group_id="P2">
          <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
          <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
        </group>
        <group group_id="P3">
          <title>HFA Nasal Aerosol Placebo</title>
          <description>HFA Nasal Aerosol Placebo once daily</description>
        </group>
        <group group_id="P4">
          <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
          <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
        </group>
        <group group_id="P5">
          <title>AQ Nasal Spray Placebo</title>
          <description>AQ Nasal Spray Placebo once daily</description>
        </group>
        <group group_id="P6">
          <title>Placebo HFA Plus Dexamethasone 6 mg</title>
          <description>Placebo HFA plus Dexamethasone 6 mg once daily. Placebo is the study control &amp; used for the study outcome analyses (CIC placebo/DEX placebo) for each delivery method (HFA or AQ). The positive control was used in a subset of the placebo subjects (18 subjects) during the last 4 days of Week 6. The active control was utilized to validate the assay sensitivity of the study, therefore this subset of placebo subjects was not included in the study outcome analyses.</description>
        </group>
        <group group_id="P7">
          <title>Placebo AQ Plus Dexamethasone 6 mg</title>
          <description>Placebo AQ plus Dexamethasone 6 mg once daily. Placebo is the study control &amp; used for the study outcome analyses (CIC placebo/DEX placebo) for each delivery method (HFA or AQ). The positive control was used in a subset of these placebo subjects (18 subjects) during the last 4 days of Week 6. The active control was utilized to validate the assay sensitivity of the study, therefore this subset of placebo subjects was not included in the study outcome analyses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="58"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
          <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
        </group>
        <group group_id="B2">
          <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
          <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
        </group>
        <group group_id="B3">
          <title>HFA Nasal Aerosol Placebo</title>
          <description>HFA Nasal Aerosol Placebo once daily</description>
        </group>
        <group group_id="B4">
          <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
          <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
        </group>
        <group group_id="B5">
          <title>AQ Nasal Spray Placebo</title>
          <description>AQ Nasal Spray Placebo once daily</description>
        </group>
        <group group_id="B6">
          <title>Placebo HFA Plus Dexamethasone 6 mg</title>
          <description>Placebo HFA plus Dexamethasone 6 mg once daily. Placebo is the study control &amp; used for the study outcome analyses (CIC placebo/DEX placebo) for each delivery method (HFA or AQ). The positive control was used in a subset of the placebo subjects (18 subjects) during the last 4 days of Week 6. The active control was utilized to validate the assay sensitivity of the study, therefore this subset of placebo subjects was not included in the study outcome analyses.</description>
        </group>
        <group group_id="B7">
          <title>Placebo AQ Plus Dexamethasone 6 mg</title>
          <description>Placebo AQ plus Dexamethasone 6 mg once daily. Placebo is the study control &amp; used for the study outcome analyses (CIC placebo/DEX placebo) for each delivery method (HFA or AQ). The positive control was used in a subset of these placebo subjects (18 subjects) during the last 4 days of Week 6. The active control was utilized to validate the assay sensitivity of the study, therefore this subset of placebo subjects was not included in the study outcome analyses.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="48"/>
            <count group_id="B5" value="58"/>
            <count group_id="B6" value="18"/>
            <count group_id="B7" value="18"/>
            <count group_id="B8" value="310"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="13.62"/>
                    <measurement group_id="B2" value="34.5" spread="13.42"/>
                    <measurement group_id="B3" value="33.0" spread="15.69"/>
                    <measurement group_id="B4" value="32.3" spread="12.53"/>
                    <measurement group_id="B5" value="35.5" spread="14.55"/>
                    <measurement group_id="B6" value="35.4" spread="12.94"/>
                    <measurement group_id="B7" value="34.0" spread="134.41"/>
                    <measurement group_id="B8" value="34.26" spread="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, customized</title>
          <units>particpants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) at Baseline</title>
        <description>AUC(0-24h) will be computed using the linear trapezoidal rule based on the actual time of serum cortisol drawing. AUC(0-24) is then approximated by the sum of the areas of trapezoids. The trapezoid for each time interval is based on the actual times of non-missing cortisol values, and is defined by the actual time interval as the base, the line connecting the two cortisol values, and the two vertical sides at the two time points. Raw data is presented for baseline values (i.e. mean/SD), while inferential statistics are presented for week 6 values (i.e. LS mean/SE).</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide hydrofluoroalkane (HFA) Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous (AQ) Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo Aqueous Nasal Spray</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) at Baseline</title>
          <description>AUC(0-24h) will be computed using the linear trapezoidal rule based on the actual time of serum cortisol drawing. AUC(0-24) is then approximated by the sum of the areas of trapezoids. The trapezoid for each time interval is based on the actual times of non-missing cortisol values, and is defined by the actual time interval as the base, the line connecting the two cortisol values, and the two vertical sides at the two time points. Raw data is presented for baseline values (i.e. mean/SD), while inferential statistics are presented for week 6 values (i.e. LS mean/SE).</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>mcg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.2" spread="61.9"/>
                    <measurement group_id="O2" value="171.7" spread="40.1"/>
                    <measurement group_id="O3" value="173.1" spread="53.5"/>
                    <measurement group_id="O4" value="172.8" spread="42.5"/>
                    <measurement group_id="O5" value="179.0" spread="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Adverse Events (AEs)</title>
        <time_frame>Weeks 0-6</time_frame>
        <population>Intent to Treat Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo Aqueous Nasal Spray</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Adverse Events (AEs)</title>
          <population>Intent to Treat Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Experiencing Adverse Events (AEs)</title>
        <time_frame>Weeks 0-6</time_frame>
        <population>Intent to Treat Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Experiencing Adverse Events (AEs)</title>
          <population>Intent to Treat Population.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="28.3"/>
                    <measurement group_id="O3" value="30.7"/>
                    <measurement group_id="O4" value="39.6"/>
                    <measurement group_id="O5" value="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Serious Adverse Events (SAEs).</title>
        <time_frame>Weeks 0-6</time_frame>
        <population>Intent to Treat Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Serious Adverse Events (SAEs).</title>
          <population>Intent to Treat Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Experiencing Serious Adverse Events (SAEs).</title>
        <time_frame>Weeks 0-6</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Experiencing Serious Adverse Events (SAEs).</title>
          <population>Intent to Treat Population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Discontinue Due to AEs</title>
        <time_frame>Weeks 0-6</time_frame>
        <population>Intent to Treat Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Discontinue Due to AEs</title>
          <population>Intent to Treat Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Discontinue Due to AEs</title>
        <time_frame>Weeks 0-6</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Discontinue Due to AEs</title>
          <population>Intent to Treat Population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Experiencing Local Nasal AEs</title>
        <description>Local Nasal adverse events are defined as adverse events occurring in the middle ear, nose, throat, and upper respiratory tract down to the larynx, anatomic regions.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo HFA Plus 6 mg Dexamethasone</title>
            <description>Placebo HFA plus 6 mg Dexamethasone once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo AQ Plus 6 mg Dexamethasone</title>
            <description>Placebo AQ plus 6 mg Dexamethasone once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Local Nasal AEs</title>
          <description>Local Nasal adverse events are defined as adverse events occurring in the middle ear, nose, throat, and upper respiratory tract down to the larynx, anatomic regions.</description>
          <population>Intent to Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Experiencing Local Nasal AEs</title>
        <description>Local Nasal adverse events are defined as adverse events occurring in the middle ear, nose, throat, and upper respiratory tract down to the larynx, anatomic regions.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
          <group group_id="O6">
            <title>Placebo HFA Plus 6 mg Dexamethasone</title>
            <description>Placebo HFA plus 6 mg Dexamethasone once daily</description>
          </group>
          <group group_id="O7">
            <title>Placebo AQ Plus 6 mg Dexamethasone</title>
            <description>Placebo AQ plus 6 mg Dexamethasone once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Experiencing Local Nasal AEs</title>
          <description>Local Nasal adverse events are defined as adverse events occurring in the middle ear, nose, throat, and upper respiratory tract down to the larynx, anatomic regions.</description>
          <population>Intent to Treat Population</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="18.3"/>
                    <measurement group_id="O3" value="14.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="19.0"/>
                    <measurement group_id="O6" value="27.8"/>
                    <measurement group_id="O7" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-12h) at Baseline</title>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-12h) at Baseline</title>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>mcg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" spread="38.3"/>
                    <measurement group_id="O2" value="95.1" spread="28.5"/>
                    <measurement group_id="O3" value="92.0" spread="31.3"/>
                    <measurement group_id="O4" value="91.9" spread="25.8"/>
                    <measurement group_id="O5" value="97.2" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-12h) From Baseline After 6 Weeks of Treatment</title>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-12h) From Baseline After 6 Weeks of Treatment</title>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>mcg•h/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="3.2"/>
                    <measurement group_id="O2" value="-1.3" spread="3.0"/>
                    <measurement group_id="O3" value="0.5" spread="3.0"/>
                    <measurement group_id="O4" value="-5.8" spread="3.0"/>
                    <measurement group_id="O5" value="-2.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Cortisol Area Under the Concentration-time Curve (AUC)(12-24h) at Baseline</title>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cortisol Area Under the Concentration-time Curve (AUC)(12-24h) at Baseline</title>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>mcg•h/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" spread="30.2"/>
                    <measurement group_id="O2" value="76.2" spread="24.0"/>
                    <measurement group_id="O3" value="81.1" spread="28.7"/>
                    <measurement group_id="O4" value="80.9" spread="26.8"/>
                    <measurement group_id="O5" value="81.8" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(12-24h) From Baseline After 6 Weeks of Treatment</title>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(12-24h) From Baseline After 6 Weeks of Treatment</title>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>mcg•h/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="2.9"/>
                    <measurement group_id="O2" value="-2.0" spread="2.7"/>
                    <measurement group_id="O3" value="-5.9" spread="2.7"/>
                    <measurement group_id="O4" value="-6.1" spread="3.7"/>
                    <measurement group_id="O5" value="2.2" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported AM Reflective TNSS</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported AM Reflective TNSS</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" spread="2.39"/>
                    <measurement group_id="O2" value="8.03" spread="2.27"/>
                    <measurement group_id="O3" value="7.81" spread="2.47"/>
                    <measurement group_id="O4" value="7.91" spread="2.50"/>
                    <measurement group_id="O5" value="7.84" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="0.29"/>
                    <measurement group_id="O2" value="-1.75" spread="0.26"/>
                    <measurement group_id="O3" value="-0.35" spread="0.27"/>
                    <measurement group_id="O4" value="-1.18" spread="0.30"/>
                    <measurement group_id="O5" value="-0.91" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported PM Reflective TNSS</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported PM Reflective TNSS</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.82" spread="2.40"/>
                    <measurement group_id="O2" value="8.39" spread="2.11"/>
                    <measurement group_id="O3" value="7.83" spread="2.52"/>
                    <measurement group_id="O4" value="8.13" spread="2.66"/>
                    <measurement group_id="O5" value="8.16" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM Reflective TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" spread="0.30"/>
                    <measurement group_id="O2" value="-1.88" spread="0.28"/>
                    <measurement group_id="O3" value="-0.31" spread="0.28"/>
                    <measurement group_id="O4" value="-1.14" spread="0.29"/>
                    <measurement group_id="O5" value="-1.19" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported AM Instantaneous TNSS</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported AM Instantaneous TNSS</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.91" spread="2.68"/>
                    <measurement group_id="O2" value="7.63" spread="2.35"/>
                    <measurement group_id="O3" value="7.37" spread="2.68"/>
                    <measurement group_id="O4" value="7.24" spread="2.43"/>
                    <measurement group_id="O5" value="7.19" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="0.27"/>
                    <measurement group_id="O2" value="-1.62" spread="0.25"/>
                    <measurement group_id="O3" value="-0.26" spread="0.25"/>
                    <measurement group_id="O4" value="-1.23" spread="0.29"/>
                    <measurement group_id="O5" value="-0.60" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported AM and PM Reflective TNSS</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported AM and PM Reflective TNSS</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68" spread="2.33"/>
                    <measurement group_id="O2" value="8.20" spread="2.14"/>
                    <measurement group_id="O3" value="7.82" spread="2.45"/>
                    <measurement group_id="O4" value="8.01" spread="2.52"/>
                    <measurement group_id="O5" value="8.01" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over Each Week, and Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over Each Week, and Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, rTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Reflective TNSS measures these symptoms over the previous 12-hour time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="0.29"/>
                    <measurement group_id="O2" value="-1.82" spread="0.27"/>
                    <measurement group_id="O3" value="-0.33" spread="0.27"/>
                    <measurement group_id="O4" value="-1.16" spread="0.29"/>
                    <measurement group_id="O5" value="-1.06" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported PM Instantaneous TNSS</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported PM Instantaneous TNSS</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.84" spread="3.09"/>
                    <measurement group_id="O2" value="7.60" spread="2.37"/>
                    <measurement group_id="O3" value="7.13" spread="2.75"/>
                    <measurement group_id="O4" value="7.38" spread="2.68"/>
                    <measurement group_id="O5" value="7.44" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported PM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported PM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.39" spread="0.28"/>
                    <measurement group_id="O2" value="-1.67" spread="0.26"/>
                    <measurement group_id="O3" value="-0.10" spread="0.26"/>
                    <measurement group_id="O4" value="-1.09" spread="0.30"/>
                    <measurement group_id="O5" value="-0.88" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported AM and PM Instantaneous TNSS</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported AM and PM Instantaneous TNSS</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" spread="2.84"/>
                    <measurement group_id="O2" value="7.62" spread="2.29"/>
                    <measurement group_id="O3" value="7.26" spread="2.67"/>
                    <measurement group_id="O4" value="7.30" spread="2.52"/>
                    <measurement group_id="O5" value="7.33" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported AM and PM Instantaneous TNSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>TNSS is the sum of individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptom on a scale of 0-3 where:
0 = absent
= mild
= moderate
= severe Therefore, iTNSS values range from 0-12 (with 0 representing an absence of symptoms and higher scores reflecting more severe symptoms). Instantaneous TNSS measures these symptoms over the previous 10 minute time interval. Difference was calculated as the six week treatment average - baseline. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="0.27"/>
                    <measurement group_id="O2" value="-1.67" spread="0.25"/>
                    <measurement group_id="O3" value="-0.19" spread="0.25"/>
                    <measurement group_id="O4" value="-1.15" spread="0.29"/>
                    <measurement group_id="O5" value="-0.75" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported Individual AM Reflective NSS</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported Individual AM Reflective NSS</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.83"/>
                    <measurement group_id="O2" value="1.65" spread="0.88"/>
                    <measurement group_id="O3" value="1.54" spread="0.89"/>
                    <measurement group_id="O4" value="1.42" spread="0.81"/>
                    <measurement group_id="O5" value="1.57" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.68"/>
                    <measurement group_id="O2" value="2.16" spread="0.63"/>
                    <measurement group_id="O3" value="2.15" spread="0.70"/>
                    <measurement group_id="O4" value="2.27" spread="0.71"/>
                    <measurement group_id="O5" value="2.06" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.85"/>
                    <measurement group_id="O2" value="1.89" spread="0.75"/>
                    <measurement group_id="O3" value="1.83" spread="0.83"/>
                    <measurement group_id="O4" value="1.85" spread="0.85"/>
                    <measurement group_id="O5" value="1.92" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="0.59"/>
                    <measurement group_id="O2" value="2.32" spread="0.57"/>
                    <measurement group_id="O3" value="2.29" spread="0.60"/>
                    <measurement group_id="O4" value="2.36" spread="0.66"/>
                    <measurement group_id="O5" value="2.29" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.09"/>
                    <measurement group_id="O2" value="-0.41" spread="0.08"/>
                    <measurement group_id="O3" value="-0.09" spread="0.08"/>
                    <measurement group_id="O4" value="-0.28" spread="0.08"/>
                    <measurement group_id="O5" value="-0.25" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.08"/>
                    <measurement group_id="O2" value="-0.50" spread="0.08"/>
                    <measurement group_id="O3" value="-0.17" spread="0.08"/>
                    <measurement group_id="O4" value="-0.36" spread="0.10"/>
                    <measurement group_id="O5" value="-0.29" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.08"/>
                    <measurement group_id="O2" value="-0.40" spread="0.08"/>
                    <measurement group_id="O3" value="-0.05" spread="0.08"/>
                    <measurement group_id="O4" value="-0.33" spread="0.09"/>
                    <measurement group_id="O5" value="-0.25" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.07"/>
                    <measurement group_id="O2" value="-0.42" spread="0.07"/>
                    <measurement group_id="O3" value="-0.05" spread="0.07"/>
                    <measurement group_id="O4" value="-0.20" spread="0.09"/>
                    <measurement group_id="O5" value="-0.13" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported Individual PM Reflective NSS</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported Individual PM Reflective NSS</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.71"/>
                    <measurement group_id="O2" value="1.87" spread="0.76"/>
                    <measurement group_id="O3" value="1.69" spread="0.81"/>
                    <measurement group_id="O4" value="1.59" spread="0.83"/>
                    <measurement group_id="O5" value="1.74" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.66"/>
                    <measurement group_id="O2" value="2.20" spread="0.58"/>
                    <measurement group_id="O3" value="2.11" spread="0.71"/>
                    <measurement group_id="O4" value="2.30" spread="0.74"/>
                    <measurement group_id="O5" value="2.16" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.83"/>
                    <measurement group_id="O2" value="2.02" spread="0.75"/>
                    <measurement group_id="O3" value="1.80" spread="0.82"/>
                    <measurement group_id="O4" value="1.93" spread="0.87"/>
                    <measurement group_id="O5" value="2.00" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="0.72"/>
                    <measurement group_id="O2" value="2.30" spread="0.54"/>
                    <measurement group_id="O3" value="2.23" spread="0.67"/>
                    <measurement group_id="O4" value="2.31" spread="0.73"/>
                    <measurement group_id="O5" value="2.25" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) From Baseline to Week 6 of the Double Blind Treatment Period</title>
        <description>Change is calculated as week 6 minus baseline. AUC(0-24h) will be computed using the linear trapezoidal rule based on the actual time of serum cortisol drawing. AUC(0-24) is then approximated by the sum of the areas of trapezoids. The trapezoid for each time interval is based on the actual times of non-missing cortisol values, and is defined by the actual time interval as the base, the line connecting the two cortisol values, and the two vertical sides at the two time points. Raw data is presented for baseline values (i.e. mean/SD), while inferential statistics are presented for week 6 values (i.e. LS mean/SE).</description>
        <time_frame>week 6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide hydrofluoroalkane (HFA) Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous (AQ) Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo Aqueous Nasal Spray</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) From Baseline to Week 6 of the Double Blind Treatment Period</title>
          <description>Change is calculated as week 6 minus baseline. AUC(0-24h) will be computed using the linear trapezoidal rule based on the actual time of serum cortisol drawing. AUC(0-24) is then approximated by the sum of the areas of trapezoids. The trapezoid for each time interval is based on the actual times of non-missing cortisol values, and is defined by the actual time interval as the base, the line connecting the two cortisol values, and the two vertical sides at the two time points. Raw data is presented for baseline values (i.e. mean/SD), while inferential statistics are presented for week 6 values (i.e. LS mean/SE).</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>mcg•h/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="5.0"/>
                    <measurement group_id="O2" value="-2.6" spread="4.6"/>
                    <measurement group_id="O3" value="-5.0" spread="4.6"/>
                    <measurement group_id="O4" value="-11.4" spread="5.7"/>
                    <measurement group_id="O5" value="-1.0" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Standard bioequivalence bounds of a 20% difference based on the clinical judgment was used to determine the delta.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority will be demonstrated if the 95% CI upper bound for the difference between ciclesonide and placebo with placebo dexamethasone (placebo minus ciclesonide) is &lt;Margin. In order to have 90% power to demonstrate non-inferiority of ciclesonide 320 μg to HFA placebo, 46 evaluable subjects per group are needed using a 1-sided alpha level of 0.025, a standard deviation of 55 μg h/dL, a non-inferiority margin of 38 μh /dL, assuming no true difference exists.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>13.0</ci_upper_limit>
            <estimate_desc>Null Hypothesis: the difference in serum cortisol levels between placebo and active (placebo-active)&gt;=38 Alternative Hypothesis: the difference in serum cortisol levels between placebo and active (placebo-active)&lt;38</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Standard bioequivalence bounds of a 20% difference based on the clinical judgment was used to determine the delta.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority will be demonstrated if the 95% CI upper bound for the difference between ciclesonide and placebo with placebo dexamethasone (placebo minus ciclesonide) is &lt;Margin. In order to have 90% power to demonstrate non-inferiority of ciclesonide 320 μg to HFA placebo, 46 evaluable subjects per group are needed using a 1-sided alpha level of 0.025, a standard deviation of 55 μg h/dL, a non-inferiority margin of 38 μh /dL, assuming no true difference exists.</non_inferiority_desc>
            <p_value>0.025</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.1</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Standard bioequivalence bounds of a 20% difference based on the clinical judgment was used to determine the delta.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority will be demonstrated if the 95% CI upper bound for the difference between ciclesonide and placebo with placebo dexamethasone (placebo minus ciclesonide) is &lt;Margin. In order to have 90% power to demonstrate non-inferiority of ciclesonide nasal spray 200 μg to placebo nasal spray 46 evaluable (per protocol) subjects per group are needed using a 1-sided alpha level of 0.025, a standard deviation of 55 μg h/dL, a non-inferiority margin of 38 μh /dL</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>25.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual PM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual PM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.09"/>
                    <measurement group_id="O2" value="-0.48" spread="0.08"/>
                    <measurement group_id="O3" value="-0.13" spread="0.08"/>
                    <measurement group_id="O4" value="-0.23" spread="0.08"/>
                    <measurement group_id="O5" value="-0.27" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.08"/>
                    <measurement group_id="O2" value="-0.48" spread="0.08"/>
                    <measurement group_id="O3" value="-0.09" spread="0.08"/>
                    <measurement group_id="O4" value="-0.37" spread="0.09"/>
                    <measurement group_id="O5" value="-0.37" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.08"/>
                    <measurement group_id="O2" value="-0.46" spread="0.08"/>
                    <measurement group_id="O3" value="-0.05" spread="0.08"/>
                    <measurement group_id="O4" value="-0.32" spread="0.09"/>
                    <measurement group_id="O5" value="-0.34" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.08"/>
                    <measurement group_id="O2" value="-0.44" spread="0.07"/>
                    <measurement group_id="O3" value="-0.04" spread="0.07"/>
                    <measurement group_id="O4" value="-0.20" spread="0.09"/>
                    <measurement group_id="O5" value="-0.21" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported Individual AM and PM Reflective NSS</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported Individual AM and PM Reflective NSS</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.73"/>
                    <measurement group_id="O2" value="1.76" spread="0.79"/>
                    <measurement group_id="O3" value="1.62" spread="0.83"/>
                    <measurement group_id="O4" value="1.51" spread="0.78"/>
                    <measurement group_id="O5" value="1.66" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="0.65"/>
                    <measurement group_id="O2" value="2.18" spread="0.59"/>
                    <measurement group_id="O3" value="2.13" spread="0.69"/>
                    <measurement group_id="O4" value="2.29" spread="0.70"/>
                    <measurement group_id="O5" value="2.11" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.83"/>
                    <measurement group_id="O2" value="1.95" spread="0.73"/>
                    <measurement group_id="O3" value="1.82" spread="0.80"/>
                    <measurement group_id="O4" value="1.89" spread="0.85"/>
                    <measurement group_id="O5" value="1.96" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="0.63"/>
                    <measurement group_id="O2" value="2.31" spread="0.53"/>
                    <measurement group_id="O3" value="2.26" spread="0.62"/>
                    <measurement group_id="O4" value="2.33" spread="0.67"/>
                    <measurement group_id="O5" value="2.27" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM and PM Reflective NSS Averaged Over the 6 Weeks of Double-blind Treatment Period</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Reflective NSS measures these symptoms over the previous 12-hour time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.09"/>
                    <measurement group_id="O2" value="-0.45" spread="0.08"/>
                    <measurement group_id="O3" value="-0.11" spread="0.08"/>
                    <measurement group_id="O4" value="-0.25" spread="0.08"/>
                    <measurement group_id="O5" value="-0.26" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.08"/>
                    <measurement group_id="O2" value="-0.50" spread="0.07"/>
                    <measurement group_id="O3" value="-0.13" spread="0.08"/>
                    <measurement group_id="O4" value="-0.37" spread="0.09"/>
                    <measurement group_id="O5" value="-0.33" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.08"/>
                    <measurement group_id="O2" value="-0.43" spread="0.08"/>
                    <measurement group_id="O3" value="-0.05" spread="0.08"/>
                    <measurement group_id="O4" value="-0.32" spread="0.09"/>
                    <measurement group_id="O5" value="-0.30" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.07"/>
                    <measurement group_id="O2" value="-0.43" spread="0.07"/>
                    <measurement group_id="O3" value="-0.04" spread="0.07"/>
                    <measurement group_id="O4" value="-0.20" spread="0.09"/>
                    <measurement group_id="O5" value="-0.17" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported Individual AM Instantaneous NSS</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported Individual AM Instantaneous NSS</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.82"/>
                    <measurement group_id="O2" value="1.43" spread="0.96"/>
                    <measurement group_id="O3" value="1.34" spread="0.94"/>
                    <measurement group_id="O4" value="1.15" spread="0.85"/>
                    <measurement group_id="O5" value="1.30" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.84"/>
                    <measurement group_id="O2" value="2.08" spread="0.66"/>
                    <measurement group_id="O3" value="2.01" spread="0.74"/>
                    <measurement group_id="O4" value="2.08" spread="0.68"/>
                    <measurement group_id="O5" value="1.93" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.86"/>
                    <measurement group_id="O2" value="1.85" spread="0.75"/>
                    <measurement group_id="O3" value="1.76" spread="0.89"/>
                    <measurement group_id="O4" value="1.76" spread="0.89"/>
                    <measurement group_id="O5" value="1.76" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="0.67"/>
                    <measurement group_id="O2" value="2.27" spread="0.58"/>
                    <measurement group_id="O3" value="2.27" spread="0.60"/>
                    <measurement group_id="O4" value="2.25" spread="0.66"/>
                    <measurement group_id="O5" value="2.20" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.08"/>
                    <measurement group_id="O2" value="-0.37" spread="0.07"/>
                    <measurement group_id="O3" value="-0.06" spread="0.08"/>
                    <measurement group_id="O4" value="-0.24" spread="0.08"/>
                    <measurement group_id="O5" value="-0.17" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.08"/>
                    <measurement group_id="O2" value="-0.47" spread="0.08"/>
                    <measurement group_id="O3" value="-0.12" spread="0.08"/>
                    <measurement group_id="O4" value="-0.36" spread="0.10"/>
                    <measurement group_id="O5" value="-0.23" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.08"/>
                    <measurement group_id="O2" value="-0.40" spread="0.07"/>
                    <measurement group_id="O3" value="-0.03" spread="0.08"/>
                    <measurement group_id="O4" value="-0.40" spread="0.09"/>
                    <measurement group_id="O5" value="-0.14" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.07"/>
                    <measurement group_id="O2" value="-0.37" spread="0.07"/>
                    <measurement group_id="O3" value="-0.05" spread="0.07"/>
                    <measurement group_id="O4" value="-0.20" spread="0.08"/>
                    <measurement group_id="O5" value="-0.06" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported Individual PM Instantaneous NSS</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported Individual PM Instantaneous NSS</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.89"/>
                    <measurement group_id="O2" value="1.51" spread="0.86"/>
                    <measurement group_id="O3" value="1.40" spread="0.93"/>
                    <measurement group_id="O4" value="1.30" spread="0.85"/>
                    <measurement group_id="O5" value="1.47" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="0.85"/>
                    <measurement group_id="O2" value="2.03" spread="0.73"/>
                    <measurement group_id="O3" value="1.98" spread="0.72"/>
                    <measurement group_id="O4" value="2.13" spread="0.75"/>
                    <measurement group_id="O5" value="2.01" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.90"/>
                    <measurement group_id="O2" value="1.88" spread="0.78"/>
                    <measurement group_id="O3" value="1.64" spread="0.84"/>
                    <measurement group_id="O4" value="1.79" spread="0.87"/>
                    <measurement group_id="O5" value="1.84" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.82"/>
                    <measurement group_id="O2" value="2.19" spread="0.59"/>
                    <measurement group_id="O3" value="2.11" spread="0.68"/>
                    <measurement group_id="O4" value="2.16" spread="0.76"/>
                    <measurement group_id="O5" value="2.12" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual PM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual PM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.08"/>
                    <measurement group_id="O2" value="-0.37" spread="0.08"/>
                    <measurement group_id="O3" value="-0.07" spread="0.08"/>
                    <measurement group_id="O4" value="-0.24" spread="0.08"/>
                    <measurement group_id="O5" value="-0.22" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.08"/>
                    <measurement group_id="O2" value="-0.45" spread="0.07"/>
                    <measurement group_id="O3" value="-0.08" spread="0.08"/>
                    <measurement group_id="O4" value="-0.33" spread="0.10"/>
                    <measurement group_id="O5" value="-0.30" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.08"/>
                    <measurement group_id="O2" value="-0.44" spread="0.07"/>
                    <measurement group_id="O3" value="0.02" spread="0.07"/>
                    <measurement group_id="O4" value="-0.35" spread="0.09"/>
                    <measurement group_id="O5" value="-0.25" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.07"/>
                    <measurement group_id="O2" value="-0.39" spread="0.07"/>
                    <measurement group_id="O3" value="0.02" spread="0.07"/>
                    <measurement group_id="O4" value="-0.15" spread="0.09"/>
                    <measurement group_id="O5" value="-0.12" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Daily Subject-reported Individual AM and PM Instantaneous NSS</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Baseline</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Daily Subject-reported Individual AM and PM Instantaneous NSS</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.83"/>
                    <measurement group_id="O2" value="1.47" spread="0.89"/>
                    <measurement group_id="O3" value="1.37" spread="0.91"/>
                    <measurement group_id="O4" value="1.22" spread="0.83"/>
                    <measurement group_id="O5" value="1.38" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.83"/>
                    <measurement group_id="O2" value="2.05" spread="0.67"/>
                    <measurement group_id="O3" value="2.00" spread="0.72"/>
                    <measurement group_id="O4" value="2.10" spread="0.69"/>
                    <measurement group_id="O5" value="1.98" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.86"/>
                    <measurement group_id="O2" value="1.87" spread="0.75"/>
                    <measurement group_id="O3" value="1.70" spread="0.84"/>
                    <measurement group_id="O4" value="1.78" spread="0.87"/>
                    <measurement group_id="O5" value="1.80" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="0.72"/>
                    <measurement group_id="O2" value="2.23" spread="0.55"/>
                    <measurement group_id="O3" value="2.19" spread="0.62"/>
                    <measurement group_id="O4" value="2.20" spread="0.68"/>
                    <measurement group_id="O5" value="2.16" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
        <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
          <group group_id="O5">
            <title>AQ Nasal Spray Placebo</title>
            <description>AQ Nasal Spray Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Subject-reported Individual AM and PM Instantaneous NSS Averaged Over the 6 Weeks of Double-blind Treatment</title>
          <description>NSS is the assessment of the individual symptoms of runny nose, sneezing, itchy nose, and nasal congestions. Subjects assess each individual symptoms on a scale of 0-3 where: 0 = absent (no sign/symptom evident);
= mild
= moderate
= severe Instantaneous NSS measures these symptoms over the previous 10 minute time interval. Difference was calculated by subtracting baseline value from the 6-week DB average. Greater reductions in the change from baseline score indicate greater improvement.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasal Sneezing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.08"/>
                    <measurement group_id="O2" value="-0.37" spread="0.07"/>
                    <measurement group_id="O3" value="-0.06" spread="0.07"/>
                    <measurement group_id="O4" value="-0.23" spread="0.08"/>
                    <measurement group_id="O5" value="-0.20" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny Nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.08"/>
                    <measurement group_id="O2" value="-0.47" spread="0.07"/>
                    <measurement group_id="O3" value="-0.10" spread="0.07"/>
                    <measurement group_id="O4" value="-0.35" spread="0.09"/>
                    <measurement group_id="O5" value="-0.27" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.08"/>
                    <measurement group_id="O2" value="-0.42" spread="0.07"/>
                    <measurement group_id="O3" value="-0.01" spread="0.07"/>
                    <measurement group_id="O4" value="-0.37" spread="0.09"/>
                    <measurement group_id="O5" value="-0.20" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.07"/>
                    <measurement group_id="O2" value="-0.39" spread="0.06"/>
                    <measurement group_id="O3" value="-0.01" spread="0.06"/>
                    <measurement group_id="O4" value="-0.17" spread="0.08"/>
                    <measurement group_id="O5" value="-0.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximal Effect Over 6 Weeks of Double-blind Treatment.</title>
        <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between each active treatment group and corresponding placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day. The evaluation is made separately for each dose level of Ciclesonide HFA compared to placebo. Difference is calculated as placebo - ciclesonide. Analysis of HFA data and AQ data were conducted separately.</description>
        <time_frame>Weeks 0-6</time_frame>
        <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximal Effect Over 6 Weeks of Double-blind Treatment.</title>
          <description>The time to maximal effect is defined as the number of days until the first treatment day on which the estimated difference between each active treatment group and corresponding placebo is at least 90% of the largest estimated difference. This is based on the analyses of change from baseline in the average of AM and PM reflective TNSS scores for each day. The evaluation is made separately for each dose level of Ciclesonide HFA compared to placebo. Difference is calculated as placebo - ciclesonide. Analysis of HFA data and AQ data were conducted separately.</description>
          <population>Per Protocol Population. Analysis does not include the subjects that received Dexamethasone during the active control period.</population>
          <units>Number of days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio (Percentage) of Correct Advances of the Dose Indicator Out of Expected Advances.</title>
        <description>Ratio of correct advance is defined as the (number of doses actuated/number of dose reported).</description>
        <time_frame>Weeks 1-2, 2-4</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio (Percentage) of Correct Advances of the Dose Indicator Out of Expected Advances.</title>
          <description>Ratio of correct advance is defined as the (number of doses actuated/number of dose reported).</description>
          <population>Intent to Treat Population</population>
          <units>percentage of correct advances</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weeks 1-2 (n=49,58,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.3" spread="10.8"/>
                    <measurement group_id="O2" value="106.2" spread="12.1"/>
                    <measurement group_id="O3" value="105.3" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 2-4 (n=46,52,71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.6" spread="11.8"/>
                    <measurement group_id="O2" value="105.9" spread="10.5"/>
                    <measurement group_id="O3" value="105.8" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Devices With Actuation Consistency</title>
        <description>Actuation consistency is defined as a dose indicator count within ±20% of the subject self report of study medication administration.</description>
        <time_frame>Weeks 1-4</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Devices With Actuation Consistency</title>
          <description>Actuation consistency is defined as a dose indicator count within ±20% of the subject self report of study medication administration.</description>
          <population>Intent to Treat Population</population>
          <units>Devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Devices With Actuation Consistency</title>
        <description>Actuation consistency is defined as a dose indicator count within ±20% of the subject self report of study medication administration.</description>
        <time_frame>Weeks 1-4</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Devices With Actuation Consistency</title>
          <description>Actuation consistency is defined as a dose indicator count within ±20% of the subject self report of study medication administration.</description>
          <population>Intent to Treat Population</population>
          <units>percentage of devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                    <measurement group_id="O2" value="92.3"/>
                    <measurement group_id="O3" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Devices With Major Discrepancies</title>
        <description>A major discrepancy is defined as a discrepancy of &gt;20 actuations between the dose indicator and subject self report of study medication administration.</description>
        <time_frame>Week 6</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
            <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Devices With Major Discrepancies</title>
          <description>A major discrepancy is defined as a discrepancy of &gt;20 actuations between the dose indicator and subject self report of study medication administration.</description>
          <population>Intent to Treat Population</population>
          <units>Devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Devices With Major Discrepancies</title>
        <description>A major discrepancy is defined as a discrepancy of &gt;20 actuations between the dose indicator and subject self report of study medication administration.</description>
        <time_frame>Week 6</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
            <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
          </group>
          <group group_id="O3">
            <title>HFA Nasal Aerosol Placebo</title>
            <description>HFA Nasal Aerosol Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Devices With Major Discrepancies</title>
          <description>A major discrepancy is defined as a discrepancy of &gt;20 actuations between the dose indicator and subject self report of study medication administration.</description>
          <population>Intent to Treat Population</population>
          <units>percentage of devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were NOT assessed for active control (Placebo plus Dexamethasone) groups.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ciclesonide HFA Nasal Aerosol 320 Mcg</title>
          <description>Ciclesonide HFA Nasal Aerosol 320 mcg once daily</description>
        </group>
        <group group_id="E2">
          <title>Ciclesonide HFA Nasal Aerosol 160 Mcg</title>
          <description>Ciclesonide HFA Nasal Aerosol 160 mcg once daily</description>
        </group>
        <group group_id="E3">
          <title>HFA Nasal Aerosol Placebo</title>
          <description>HFA Nasal Aerosol Placebo once daily</description>
        </group>
        <group group_id="E4">
          <title>Ciclesonide Aqueous Nasal Spray 200 Mcg</title>
          <description>Ciclesonide Aqueous Nasal Spray 200 mcg once daily</description>
        </group>
        <group group_id="E5">
          <title>AQ Nasal Spray Placebo</title>
          <description>AQ Nasal Spray Placebo once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyphthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Instillation site discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Myaglia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Drug withdrawal headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E5" events="11" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E4" events="16" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E5" events="7" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nasal septum disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Dose levels investigated were higher than the US FDA approved dose (74 mcg once daily) for allergic rhinitis subjects. Publication references to 148 and 282mcg are equivalent to 160 and 320mcg.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

